Rare Silent Variant in MODY: Clinical Challenges and Variable Expressivity in a Family Affected by HNF1A Maturity-Onset Diabetes of the Young

A case study published in the journal Cureus on June 18, 2026, describes a family with a rare silent variant of the HNF1A gene causing Maturity-Onset Diabetes of the Young (MODY). The report demonstrates how a single genetic mutation can result in widely different clinical presentations, known as variable expressivity, among related individuals.

The Cureus report details the challenges of diagnosing monogenic diabetes when patients do not fit the typical profile of Type 1 or Type 2 diabetes. The researchers found that the family’s specific HNF1A mutation led to varying levels of glucose intolerance and different ages of onset across family members.

HNF1A-MODY is a form of diabetes caused by mutations in the hepatocyte nuclear factor 1-alpha gene. This gene is critical for the proper functioning of beta cells in the pancreas, which produce insulin.

Why is HNF1A-MODY often misdiagnosed?

HNF1A-MODY often mimics other forms of diabetes, leading clinicians to prescribe incorrect treatments. According to the Cureus study, patients may be misidentified as having Type 1 diabetes because they are often young at the time of diagnosis.

They may also be mistaken for Type 2 diabetes patients if they exhibit obesity or a strong family history of metabolic issues. However, unlike Type 1 diabetes, MODY patients typically do not have the same autoimmune markers, such as islet cell antibodies.

The Cureus researchers noted that the “variable expressivity” in this family meant some members showed severe hyperglycemia while others remained relatively stable, further complicating the initial clinical picture.

What makes a silent variant difficult to detect?

A silent variant, or synonymous mutation, is a genetic change that does not alter the amino acid sequence of the resulting protein. Because the protein sequence remains the same, these mutations are often overlooked during standard genetic screenings.

The Cureus report explains that these variants can still cause disease by affecting how the gene is spliced or how much of the protein is produced. This creates a diagnostic gap where a patient has a clear genetic cause for their diabetes, but the mutation remains “invisible” to basic testing.

Identifying these variants requires more advanced genomic sequencing and functional analysis to determine if the mutation actually disrupts cellular function.

How does the treatment for MODY differ from standard diabetes care?

The primary clinical importance of an HNF1A-MODY diagnosis is the shift in medication. Many patients with this specific mutation are hypersensitive to sulfonylureas, a class of drugs that stimulate insulin secretion.

According to the study, patients with HNF1A-MODY can often transition from insulin injections to low-dose oral sulfonylureas. This transition typically results in better glycemic control and a higher quality of life compared to lifelong insulin dependence.

The Cureus report emphasizes that without genetic confirmation, patients remain on insulin unnecessarily, missing the opportunity for a more targeted pharmaceutical approach.

What are the implications for family screening?

Because MODY is an autosomal dominant condition, there is a 50% chance that a parent will pass the mutation to their children. The Cureus case highlights that the presence of the mutation does not guarantee the same severity of the disease for every family member.

This variation means that family members who appear healthy may still carry the variant and could develop diabetes later in life. The researchers suggest that once a pathogenic variant is identified in one family member, targeted screening for other relatives is essential for early intervention.

Early detection allows clinicians to monitor blood glucose levels more closely and initiate sulfonylurea therapy as soon as the disease manifests, preventing the long-term complications associated with poorly managed hyperglycemia.